^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CTM-N2D
i
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
CytoMed Therap
Drug class:
γδ TCR modulator, NKG2DL-targeted CAR-T immunotherapy
Related drugs:
Phase 1
CytoMed Therapeutics Pte Ltd
Not yet recruiting
Last update posted :
03/31/2022
Initiation :
04/01/2022
Primary completion :
03/01/2023
Completion :
12/01/2023
NKG2D
|
CTM-N2D
Share
